Skip Navigation
Department of Health and Human Services www.hhs.gov
  • CME/CE Activities
  • Preventing Fractures in Patients with Osteoporosis or Low Bone Density
 
This website is iPhone friendly.

This CME/CE activity is provided by PRIME Education, Inc. (PRIME®) and is accredited for a multi-disciplinary audience of health care practitioners. This activity is supported by contract number HHSA290201200021I from the Agency for Healthcare Research and Quality. User data collected through this activity will reside on PRIME's educational portal for use by AHRQ.

Preventing Fractures in Patients with Osteoporosis or Low Bone Density: A Review of the Evidence

To Receive a Certificate for This Activity:

Course Image
  1. 1. Read the Program Overview on this page.
  2. 2. Review the Faculty Biographies, Accreditation Statements, and Disclosure tabs.
  3. 3. Access the Activity in full.
  4. 4. Complete the Post-Test & Evaluation.
  5. 5. A printable certificate will be available immediately following the activity.

Program Overview

Activity Description

Osteoporosis is a skeletal disease which causes bone tissue loss, and is associated with disability, chronic pain, and an increased risk of bone fractures. In 2007, due to the increasing prevalence and costs associated with osteoporosis, the Agency for Healthcare Research and Quality (AHRQ) commissioned a systematic review of the literature on the comparative efficacy and harms of treatments for preventing osteoporotic fractures. Since the release of the original report, new formulations of bisphosphonates and a new biologic agent, denosumab, have become available in the US, prompting an update of the review.

This interactive HD video program summarizes data from this comprehensive review, allowing healthcare professionals to better understand the efficacy and safety of therapies used to prevent osteoporotic fractures, as well as the effects of risk factors, adherence, bone density monitoring, and long-term therapy on outcomes for patients with osteoporosis. In addition, practical application of the AHRQ findings will be presented to empower clinicians with the knowledge needed to provide evidence-based care for their patients.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Compare the efficacy and risks of various treatments to reduce the risk of osteoporotic fractures
  • Assess the effect of adherence on treatment efficacy
  • Evaluate the harms related to therapies among specific patient subpopulations
  • Establish the effects of bone mineral density monitoring and long-term use of antifracture treatment on outcomes

Target Audience

This CME activity is designed to meet the educational needs of physicians, physician assistants, nurse practitioners, pharmacists, nurses, case managers, health education specialists and medical assistants.

Method of Participation

To receive a certificate for this activity, you should:

  • Complete the learner assessment pretest
  • View the entire activity online
  • Complete an online evaluation & post-test
  • Print your certificate online

The estimated time to complete this activity, including review of the materials, is 1.0 hour.

Term of Approval

April 30, 2012 through April 29, 2014. Original release date: April 30, 2012.

Acknowledgement of Support

There is no fee for this CME/CE activity. This activity is sponsored by PRIME Education, Inc (PRIME®) and funded under contract HHSA290201200021I from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS).

Faculty Biographies and Disclosures

Click faculty name to view full biography.

Speaker

Silvina Levis, MD
Director, Osteoporosis Center
Professor of Medicine
University of Miami Miller School of Medicine
Director of Clinical Protocol Development
Geriatric Research, Education, and Clinical Center (GRECC)
Miami VA Medical Center
Miami, FL

Planner

Carolyn LePage, PhD, ARNP
Assistant Professor
Barry University School of Nursing
Miami Shores, FL

Planner

Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
National Clinical Nursing Director
Department of Neurology
Multiple Sclerosis Center of Excellence, East
Veterans Affairs Medical Center
Adjunct Faculty
Trinity Nursing Program School of Professional Studies
Trinity Washington University
Clinical Preceptor and Instructor
Advanced Practice Programs
The Catholic University of America School of Nursing
Washington, DC

Planner

Michele B Kaufman, PharmD, CGP, RPh
President, PRN Communications Inc.
Editor, Pharmacovigilance Forum, P&T Journal
NYCSHP Secretary
Adjunct Faculty
Touro College of Pharmacy
New York, NY

Planner

Wanda F Carter, MPH, CHES
Adjunct Professor, Kaplan University Master of Public Health Program
Adjunct Professor, Axia College (U of Phoenix) Health Care Administration Program
Adjunct Professor, LA College International Health Care Administration Program
Adjunct Professor, Ashford University Health Care Administration Program
PHPS Alumnus, CDC Scientific Education and Professional Development Program Office

Peer Reviewer

Richard K Mastrole, MD
Internal Medicine and Rheumatology
Holy Cross Medical Group
Ft Lauderdale, FL

Peer Reviewer

Joyce M Knestrick, PhD, CRNP, FAANP
Coordinator of Graduate Education
Frontier School of Midwifery and Family Nursing
Certified Family Nurse Practitioner
The Primary Care Center
Mt Morris, PA

Peer Reviewer

Mary Elizabeth Elliott, PharmD, PhD
Associate Professor and Vice-Chair, Pharmacy Practice Division
School of Pharmacy, University of Wisconsin-Madison
Clinical Pharmacist
Osteoporosis Clinic, Veterans Affairs Medical Center
Madison WI

Peer Reviewer

Kathleen A Jarvis, MS, RN, CCM
Clinical Educator
Alere Healthcare
Fort Lauderdale, FL

Begin Activity

Accreditation/Credit Designation

Physician Credit Designation Statement

A C C M E Logo

PRIME Education, Inc. (PRIME®) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

PRIME® designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistant Accreditation Statement

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hours of Category I credit for completing this program.

Nurse Practitioner Accreditation Statement

Nurse Practitioner Logo

PRIME Education, Inc (PRIME®) is approved as a provider of Nurse Practitioner Continuing Education by the American Association of Nurse Practitioners. Provider number: 060815. This program is accredited for 1.0 contact hour. Program ID# CER29.

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

Pharmacist Accreditation StatementA C P E Logo

PRIME® is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This curriculum has been approved for 1.0 contact hour (0.1 CEUs) by PRIME®. The Universal Activity Number for this program is 0255-0000-12-018-H01-P. This learning activity is Knowledge-Based.

Nurse Accreditation StatementA N C C Logo

PRIME Education, Inc. (PRIME®) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

PRIME® designates this activity for 1.0 contact hour.

Case Manager Accreditation Statement

The Commission for Case Manager Certification designates this educational activity for 1.0 contact hour for certified case managers.

Medical Assistant Accreditation Statement

This program has been granted prior approval by the American Association of Medical Assistants (AAMA) for 1.0 Continuing Education unit. Approval #122516 . Granting approval in no way constitutes endorsement by the AAMA of the program content or the program's sponsor.

Certified Health Education Specialist Accreditation Statement

Sponsored by PRIME Education, Inc. (PRIME®), a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc.

This program is designated for Certified Health Education Specialists (CHES) to receive up to 1.0 Category I contact hours in health education.

CHES Provider Number: MEP3774

Begin Activity

Faculty Disclosures

Faculty Name
Advisory Board Consultant Grants / Research Salary / Contractual Supported Promotional Education Stock / Shareholder Other Financial Support
Silvina Levis, MD
Speaker
None None None None None None None
Carolyn LePage, PhD, ARNP
Planner
None None None Barry University None None None
Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
Planner
sanofi-aventis None None None None None None
Michele B Kaufman, PharmD, CGP, RPh
Planner
None OrthoMcNeil Janssen None None None None None
Wanda F Carter, MPH, CHES
Planner
None None None None None None None
Richard K Mastrole, MD
Reviewer
None None None None None None None
Joyce M Knestrick, PhD, CRNP, FAANP
Reviewer
None None None None None None None
Mary Elizabeth Elliott, PharmD, PhD
Reviewer
None None None None None None None
Kathleen A Jarvis, MS, RN, CCM
Reviewer
None None None None None None None
Chris R Prostko, PhD
Scientific Program Director
NoneNoneNonePRIME®NoneNoneNone
Lynn Goldenberg, RN, BSN
Director of Accreditation & Compliance
NoneNoneNonePRIME®NoneNoneNone

Disclosure Policy

PRIME Education Inc (PRIME®) endorses the standards of the ACCME, as well as those of the AANP, ANCC and ACPE, that require everyone in a position to control the content of a CME/CE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CE activity. CME/CE activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when individuals in a position to control the content of CME/CE have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.

PRIME® willidentify, review and resolve all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff are provided with this activity.

Presentations that provide information in whole or in part related to non FDA approved uses of drugs and/or devices will disclose the unlabeled indications or the investigational nature of their proposed uses to the audience. Participants should refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Participants should verify all information and data before treating patients or employing any therapies prescribed in this educational activity. The opinions expressed in the educational activity are those of the presenting faculty and do not necessarily represent the views of PRIME®, the ACCME, AANP, ACPE, ANCC and other relevant accreditation bodies.

Content validation methods are consistently utilized by PRIME® to ensure that all program content is evidence-based, fair-balanced, and developed with scientific rigor and integrity. All clinical recommendations are based on evidence accepted within the medical profession. All scientific research referred to, reported or used to support a clinical recommendation conforms to accepted standards of experimental design, data collection and analysis. In addition to review of content by course directors and expert faculty, content is also validated through independent peer reviewers selected for their expertise in the content area, as well as their experience in the intended audience. All peer reviewers, planners, course directors, faculty and relevant staff utilized by PRIME® complete disclosures which are related to their role in the educational activity.

Accessibility

PRIME®is committed to providing access to our CME programs for individuals with disabilities as identified in Section 508 of the Rehabilitation Act for all web-based programs. This website is 508 compliant.

Begin Activity

Pretest

To access the activity, please complete this brief Pretest.

  • Returning user? Login Here!
  1. Before accessing this educational activity, were you aware of the AHRQ-supported comparative effectiveness research on treatment to prevent fractures in low bone density or osteoporosis?

  2. A decrease in bone mass is the hallmark of osteoporosis. According to the National Osteoporosis Foundation a 49-year-old woman should have bone mass density (BMD) classified by which of the following criteria?

  3. Which of the following statements is accurate concerning an increased risk of adverse effects among patients treated with these therapies?

  4. How would you describe your current level of confidence in applying comparative effectiveness research on treatment to prevent fractures in low bone density or osteoporosis?

  5. How valuable is comparative effectiveness research on treatment to prevent fractures in low bone density or osteoporosis in making patient-centered treatment and management decisions?

  6. Numerous approved therapies are available for the treatment of osteoporosis for the prevention of fractures. Both risk factors and bone mass density scoring systems are incorporated in the criteria for choosing the most appropriate therapies for each patient. Which treatment(s) would you likely recommend for a 67-year-old postmenopausal woman with elevated blood pressure and osteoporosis, who may be at risk for vertebral and hip fracture?

  7. If you had a clinician guide/consumer guide on treatment to prevent fractures in low bone density or osteoporosis, what would you most likely do?

Post-Test & Evaluation

You must access the activity before receiving credit!

Clinician & Consumer Summaries on Osteoporotic Fractures

Download these free summaries for your reference and/or patient handouts. You may also order bulk copies free of charge from the AHRQ Publication Clearinghouse below.

AHRQ Clearinghouse Bulk Order Form

Returning user? Login Here
  • (Limit 200)
  • (This answer helps stop spam )
  • Alternatively, you can call the AHRQ Publications Clearinghouse at 1-800-358-9295. Reference the title and product number above.